Brazil’s antitrust regulator CADE announced on Wednesday, January 20, it had cleared the way for Hypera Pharma to buy a portfolio of productions from Japan’s Takeda Pharmaceutical.
According to a source familiar with the matter, there was only one restriction, and it involved the medicine Xantinon, which Hypera has already sold locally to União Química Farmacêutica Nacional. Hypera had told investors it was expecting this approval in early 2021.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Supreme Court Declines to Hear Realtors’ Appeal, DOJ Antitrust Probe Moves Forward
Jan 13, 2025 by
CPI
Commerzbank Chairman Doubts Amicable Merger with UniCredit After Stake Acquisition
Jan 13, 2025 by
CPI
Senator Warren Presses HUD Nominee on Rent Price-Fixing
Jan 13, 2025 by
CPI
Epic Games CEO Accuses Tech Giants of Shifting Loyalties to Court Trump Administration
Jan 13, 2025 by
CPI
Apple’s New Developer Fees Face Renewed Scrutiny from EU Antitrust Regulators
Jan 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand